ISSN: 3030-3931, Impact factor: 7,241
Volume 7, issue 1, Aprel 2025
https://worldlyjournals.com/index.php/Yangiizlanuvchi
worldly knowledge
OAK Index bazalari :
research gate, research bib.
Qo’shimcha index bazalari:
zenodo, open aire. google scholar.
Original article
163
PATHOPHYSIOLOGY OF HEPATORENAL SYNDROME: A COMPREHENSIVE
REVIEW
D.R. Abdullayeva,
Urgench Branch of Tashkent Medical Academy, Urgench, Uzbekistan
I.Sh. Bobojonov
Urgench Branch of Tashkent Medical Academy, Urgench, Uzbekistan
Abstract:
Hepatorenal Syndrome (HRS) is a grave complication of advanced liver disease,
characterized by functional renal failure in the absence of underlying structural kidney pathology.
The pathogenesis of HRS is multifactorial and deeply intertwined with the complex
hemodynamic changes that occur in cirrhosis. The hallmark features include splanchnic arterial
vasodilation, systemic circulatory dysfunction, renal vasoconstriction, and impaired renal
autoregulation. Neurohormonal activation, particularly the renin-angiotensin-aldosterone system
(RAAS), sympathetic nervous system (SNS), and non-osmotic vasopressin release, plays a
pivotal role. Emerging evidence highlights the role of systemic inflammation, bacterial
translocation, and immune dysregulation in the progression of renal dysfunction in cirrhosis.
This article explores the detailed pathophysiology of HRS, from its historical development to
molecular mechanisms, and discusses how this understanding informs clinical management and
therapeutic development.
Keywords:
Hepatorenal syndrome; Pathophysiology; Cirrhosis; Renal vasoconstriction;
Splanchnic vasodilation; Systemic inflammation; Portal hypertension; Neurohormonal activation;
Nitric oxide; RAAS; AKI in cirrhosis.
Introduction
Hepatorenal Syndrome (HRS) represents one of the most serious complications of end-stage
liver disease and portal hypertension. It is defined as a functional renal impairment occurring in
patients with advanced hepatic dysfunction, particularly cirrhosis, without any structural damage
to the kidneys. Unlike other causes of acute kidney injury (AKI), HRS is uniquely characterized
by intense renal vasoconstriction occurring in the setting of systemic and splanchnic arterial
vasodilation.
Understanding the pathophysiology of HRS is essential not only for accurate diagnosis but also
for timely and effective intervention. The traditional perspective of HRS as merely a circulatory
disorder has evolved into a broader understanding that includes immune dysregulation, systemic
inflammation, and endothelial dysfunction. This article provides a detailed exploration of the
current understanding of the mechanisms driving HRS, tracing the hemodynamic, molecular, and
immunological pathways that culminate in renal hypoperfusion and failure.
Historical Perspectives on HRS Pathophysiology
The understanding of Hepatorenal Syndrome has evolved significantly over the past century. In
the early 20th century, renal dysfunction in patients with liver failure was attributed primarily to
hypovolemia or nephrotoxic insults. However, by the 1950s and 60s, autopsy studies began
ISSN: 3030-3931, Impact factor: 7,241
Volume 7, issue 1, Aprel 2025
https://worldlyjournals.com/index.php/Yangiizlanuvchi
worldly knowledge
OAK Index bazalari :
research gate, research bib.
Qo’shimcha index bazalari:
zenodo, open aire. google scholar.
Original article
164
showing normal renal histology in patients with renal failure secondary to cirrhosis, suggesting a
functional, rather than structural, basis.
The term “Hepatorenal Syndrome” was formally introduced in the mid-20th century to describe
this phenomenon. The International Ascites Club (IAC) played a pivotal role in refining its
diagnostic criteria and in drawing attention to the unique pathophysiological mechanisms
underpinning the condition. Over time, the focus of research shifted from mere clinical
observation to understanding the intricate hemodynamic and neurohormonal alterations that
characterize HRS. Technological advancements in imaging, renal biomarkers, and molecular
biology have further expanded the framework through which HRS is understood today.
Hemodynamic Basis of HRS
The Central Role of Portal Hypertension and Cirrhosis
Cirrhosis, the most common underlying condition in HRS, leads to increased intrahepatic
resistance and the development of portal hypertension. This elevation in portal pressure sets off a
cascade of systemic circulatory disturbances that underlie the pathogenesis of HRS. One of the
earliest responses to portal hypertension is splanchnic arterial vasodilation, driven largely by
increased production of vasodilators such as nitric oxide (NO).
Splanchnic Vasodilation
Splanchnic vasodilation is a hallmark feature in the pathogenesis of HRS. The splanchnic
circulation includes the arteries supplying the gastrointestinal tract, liver, spleen, and pancreas.
In cirrhosis, there is upregulation of vasodilatory mediators, especially nitric oxide synthase
(NOS), prostacyclins, and endocannabinoids, which contribute to profound vasodilation in the
splanchnic bed. This vasodilation, though initially compensatory, leads to effective arterial
hypovolemia — a perceived reduction in blood volume despite normal or increased plasma
volume.
Arterial Underfilling Hypothesis
The arterial underfilling hypothesis remains central to understanding HRS. It posits that the
vasodilation in the splanchnic bed leads to a fall in systemic vascular resistance and arterial
pressure. In response, the div activates vasoconstrictor systems to maintain perfusion pressure
— notably the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system
(SNS), and antidiuretic hormone (ADH) secretion.
While these systems maintain blood pressure, they also contribute to progressive renal
vasoconstriction and sodium/water retention, ultimately impairing glomerular filtration. Thus,
renal hypoperfusion in HRS is not due to hypovolemia per se, but rather due to a complex
redistribution of blood flow and pathological neurohormonal activation.
Renal Vasoconstriction and Autoregulatory Failure
Under normal conditions, the kidneys possess robust autoregulatory mechanisms that maintain a
stable glomerular filtration rate (GFR) across a wide range of perfusion pressures. These
ISSN: 3030-3931, Impact factor: 7,241
Volume 7, issue 1, Aprel 2025
https://worldlyjournals.com/index.php/Yangiizlanuvchi
worldly knowledge
OAK Index bazalari :
research gate, research bib.
Qo’shimcha index bazalari:
zenodo, open aire. google scholar.
Original article
165
mechanisms include afferent arteriolar dilation, efferent arteriolar constriction, and
tubuloglomerular feedback.
In HRS, these autoregulatory processes are overridden by intense renal vasoconstriction.
Afferent arteriolar tone is markedly increased due to elevated levels of vasoconstrictors such as
angiotensin II, norepinephrine, and endothelin-1, along with diminished intrarenal vasodilators
like prostaglandins and NO. The net result is a significant drop in renal plasma flow and GFR.
Furthermore, the renal vasoconstriction in HRS is "functional"—meaning the kidneys
themselves are structurally normal. This is evidenced by the dramatic improvement in renal
function following liver transplantation or pharmacologic reversal of vasoconstriction using
agents like terlipressin. However, if untreated, prolonged renal hypoperfusion may lead to
ischemic injury and structural damage, transitioning from functional HRS to acute tubular
necrosis (ATN).
Neurohormonal Activation
The neurohormonal response to arterial underfilling plays a crucial role in the progression of
HRS. In response to decreased effective circulating volume, the div activates several systems
aimed at preserving perfusion to vital organs. However, these same mechanisms become
maladaptive in HRS, especially in the kidneys.
Renin-Angiotensin-Aldosterone System (RAAS)
One of the earliest responses to splanchnic vasodilation is activation of the RAAS.
Juxtaglomerular cells in the kidneys sense decreased perfusion pressure and sodium delivery,
leading to increased renin release. Renin converts angiotensinogen to angiotensin I, which is
subsequently transformed into angiotensin II by angiotensin-converting enzyme (ACE).
Angiotensin II is a potent vasoconstrictor, particularly of the efferent arteriole, and stimulates
aldosterone secretion from the adrenal cortex. Aldosterone promotes sodium and water retention
in the distal nephron. While these changes help maintain systemic blood pressure, they reduce
renal perfusion and further impair natriuresis and diuresis. Over time, persistent RAAS
activation leads to volume expansion, ascites formation, and worsening renal vasoconstriction.
Sympathetic Nervous System (SNS)
The SNS is also strongly activated in cirrhosis and HRS. Baroreceptors in the aortic arch and
carotid sinus detect hypotension and initiate reflex sympathetic discharge. This causes
vasoconstriction of the renal vasculature, increased cardiac output (in early stages), and
enhanced sodium reabsorption in the proximal tubules.
Chronic SNS activation results in elevated plasma norepinephrine levels, which correlate with
disease severity and poor prognosis in HRS. In severe cases, SNS overactivity contributes to a
hyperdynamic but ineffective circulatory state with persistently low renal perfusion.
Arginine Vasopressin (AVP) / Antidiuretic Hormone (ADH)
ISSN: 3030-3931, Impact factor: 7,241
Volume 7, issue 1, Aprel 2025
https://worldlyjournals.com/index.php/Yangiizlanuvchi
worldly knowledge
OAK Index bazalari :
research gate, research bib.
Qo’shimcha index bazalari:
zenodo, open aire. google scholar.
Original article
166
Non-osmotic release of AVP from the posterior pituitary is a hallmark of advanced cirrhosis.
Normally triggered by hyperosmolality, AVP release in cirrhosis is primarily driven by arterial
underfilling and hypotension.
AVP acts on V2 receptors in the renal collecting ducts, promoting free water reabsorption and
contributing to dilutional hyponatremia — a common feature of decompensated liver disease. It
also exerts vasoconstrictive effects through V1 receptors, further compromising renal blood flow.
Role of Nitric Oxide and Vasodilatory Mediators
Increased production of vasodilatory substances is a cornerstone of the pathophysiology of HRS,
particularly in the splanchnic circulation.
Nitric Oxide (NO)
Endothelial nitric oxide synthase (eNOS) is upregulated in the liver and splanchnic vessels of
patients with cirrhosis. Portal hypertension and bacterial translocation lead to the release of
inflammatory cytokines (e.g., TNF-α, IL-6), which stimulate eNOS and inducible NOS (iNOS),
causing massive NO overproduction.
NO mediates smooth muscle relaxation by increasing intracellular cyclic guanosine
monophosphate (cGMP), resulting in decreased vascular tone. The vasodilation is primarily
confined to the splanchnic bed, creating a state of relative hypovolemia that prompts
compensatory vasoconstriction elsewhere, especially in the kidneys.
Other Vasodilators: Prostacyclins, CO, Endocannabinoids
Prostacyclins (PGI2): Increase vasodilation and inhibit platelet aggregation; their overproduction
contributes to systemic hypotension.
Carbon Monoxide (CO): Produced by heme oxygenase activity; plays a role similar to NO in
vasodilation.
Endocannabinoids: Activate cannabinoid receptors in vascular smooth muscle, causing
additional vasodilation in cirrhotic patients.
Together, these mediators amplify the splanchnic vasodilation, reduce effective arterial volume,
and perpetuate the cycle of renal hypoperfusion.
Cytokines, Endotoxemia, and Systemic Inflammation
Emerging evidence suggests that systemic inflammation and immune dysregulation are critical
contributors to the development and progression of HRS.
Bacterial Translocation and Endotoxemia
In cirrhosis, increased intestinal permeability and impaired gut motility allow translocation of
bacteria and endotoxins (lipopolysaccharides, LPS) into the portal and systemic circulation. This
ISSN: 3030-3931, Impact factor: 7,241
Volume 7, issue 1, Aprel 2025
https://worldlyjournals.com/index.php/Yangiizlanuvchi
worldly knowledge
OAK Index bazalari :
research gate, research bib.
Qo’shimcha index bazalari:
zenodo, open aire. google scholar.
Original article
167
microbial invasion stimulates hepatic Kupffer cells and systemic monocytes to release pro-
inflammatory cytokines such as TNF-α, IL-1β, and IL-6.
These cytokines not only promote vasodilation via NO and prostaglandins but also directly
damage endothelial cells, disrupting vascular tone regulation. Endotoxemia has been implicated
in the triggering of HRS, especially in the context of spontaneous bacterial peritonitis (SBP).
Systemic Inflammatory Response Syndrome (SIRS)
Many patients with HRS exhibit signs of SIRS — fever, leukocytosis, and elevated CRP — even
in the absence of overt infection. This inflammatory response exacerbates circulatory
dysfunction and contributes to vascular leakage, impaired renal perfusion, and microcirculatory
collapse.
Immune-Mediated Renal Dysfunction
Cytokine-induced activation of renal tubular cells, leukocyte infiltration, and upregulation of
adhesion molecules may further impair renal function. This emerging “inflammatory hypothesis”
of HRS challenges the classical view of the syndrome as purely hemodynamic, proposing a role
for immune modulation in its treatment.
Bacterial Translocation and the Gut-Liver Axis
The interplay between the gut, liver, and kidneys—commonly referred to as the gut-liver-kidney
axis—is a pivotal aspect of HRS pathophysiology. One of the key elements in this axis is
bacterial translocation (BT), which refers to the migration of viable bacteria or bacterial products
(e.g., endotoxins, lipopolysaccharides) from the intestinal lumen to mesenteric lymph nodes,
systemic circulation, and eventually to extraintestinal organs.
Pathophysiology of Bacterial Translocation
In cirrhosis, several factors promote BT:
Intestinal dysbiosis: An altered microbiota composition with overgrowth of pathogenic bacteria.
Increased intestinal permeability: “Leaky gut” due to disrupted tight junctions in enterocytes.
Impaired immune surveillance: Reduced mucosal immunity and defective macrophage function.
Slow intestinal motility: Promotes bacterial overgrowth and stagnation.
These changes result in the constant presence of low-grade endotoxemia in cirrhotic patients,
especially those with ascites or spontaneous bacterial peritonitis (SBP).
BT and HRS Progression
ISSN: 3030-3931, Impact factor: 7,241
Volume 7, issue 1, Aprel 2025
https://worldlyjournals.com/index.php/Yangiizlanuvchi
worldly knowledge
OAK Index bazalari :
research gate, research bib.
Qo’shimcha index bazalari:
zenodo, open aire. google scholar.
Original article
168
Once bacterial products reach systemic circulation, they trigger widespread activation of pattern
recognition receptors (like TLR4) on immune cells, leading to cytokine release and endothelial
activation. This causes:
Increased nitric oxide production
Capillary leak and fluid shift
Renal vasoconstriction due to systemic inflammation
Diminished responsiveness of the kidneys to vasodilatory stimuli
BT also worsens portal hypertension, reinforcing the vicious cycle of circulatory dysfunction and
renal hypoperfusion.
Hepatic and Renal Endothelial Dysfunction
The vascular endothelium plays a central role in regulating vascular tone, permeability, and
blood flow. In HRS, both hepatic and renal endothelial functions are profoundly impaired.
Hepatic Endothelial Dysfunction
In cirrhosis, liver sinusoidal endothelial cells (LSECs) lose their fenestrations, and the hepatic
microcirculation becomes capillarized. This reduces hepatic clearance of vasodilators like NO
and endotoxins, promoting systemic circulation of harmful mediators. Hepatic stellate cells,
when activated, produce extracellular matrix and vasoconstrictors like endothelin-1, further
raising intrahepatic resistance and worsening portal hypertension.
Renal Endothelial Dysfunction
Renal microvascular endothelial cells also exhibit dysfunction:
Increased endothelin-1 production causes strong vasoconstriction of afferent arterioles.
Reduced availability of NO and prostaglandins contributes to persistent renal vasoconstriction.
Microvascular thrombosis and endothelial cell activation can lead to structural renal injury if
prolonged.
These changes compromise renal autoregulation and make the kidneys highly sensitive to further
drops in perfusion.
Role of Cardiac Dysfunction in HRS (Cirrhotic Cardiomyopathy)
The role of cardiac function in the pathogenesis of HRS has gained increasing attention,
particularly the condition known as cirrhotic cardiomyopathy.
Definition and Characteristics
ISSN: 3030-3931, Impact factor: 7,241
Volume 7, issue 1, Aprel 2025
https://worldlyjournals.com/index.php/Yangiizlanuvchi
worldly knowledge
OAK Index bazalari :
research gate, research bib.
Qo’shimcha index bazalari:
zenodo, open aire. google scholar.
Original article
169
Cirrhotic cardiomyopathy refers to a state of impaired cardiac contractile response to stress (e.g.,
volume overload, pharmacologic stimuli) in the setting of normal or elevated baseline cardiac
output. It is characterized by:
Blunted systolic and diastolic responses
Electrophysiological abnormalities (e.g., QT interval prolongation)
Altered beta-adrenergic receptor signaling
Despite a hyperdynamic circulation (elevated cardiac output and low systemic vascular
resistance), the heart is often unable to respond appropriately to physiological demands,
especially during infections, paracentesis, or other stressors.
Impact on Renal Function
As cirrhotic cardiomyopathy progresses:
Renal perfusion becomes increasingly dependent on cardiac output.
Decreased cardiac response leads to inadequate renal blood flow, exacerbating HRS.
Cardiorenal syndrome type 1 (acute decompensated heart failure leading to renal failure) may
overlap with HRS in some patients.
Recent studies show that left atrial dysfunction, impaired ventricular compliance, and subclinical
myocardial fibrosis are common in advanced liver disease and may contribute to reduced
effective renal perfusion even before classical HRS criteria are met.
Conclusion
Hepatorenal Syndrome (HRS) represents a complex and life-threatening complication of
advanced liver disease, reflecting the culmination of intricate interactions between the liver,
kidneys, vascular system, heart, immune system, and gut microbiota. The pathophysiology of
HRS, once believed to be solely due to hemodynamic alterations, is now understood as a
multifaceted process involving intense splanchnic vasodilation, systemic circulatory dysfunction,
neurohormonal activation, and profound renal vasoconstriction.
Emerging insights into the roles of inflammatory mediators, endothelial dysfunction, and genetic
predisposition have further refined our understanding of disease mechanisms. In particular, the
interplay between bacterial translocation, the gut-liver axis, and systemic inflammation has
highlighted new therapeutic opportunities aimed at modulating immune responses and improving
endothelial health.
Clinically, a deeper grasp of HRS pathogenesis has translated into earlier detection, better risk
stratification, and targeted therapies, including the use of vasoconstrictors, albumin, and
preventative strategies against infections. The redefinition of HRS into acute and chronic forms
ISSN: 3030-3931, Impact factor: 7,241
Volume 7, issue 1, Aprel 2025
https://worldlyjournals.com/index.php/Yangiizlanuvchi
worldly knowledge
OAK Index bazalari :
research gate, research bib.
Qo’shimcha index bazalari:
zenodo, open aire. google scholar.
Original article
170
underscores its dynamic and progressive nature, reinforcing the need for vigilance in cirrhotic
patients.
Ultimately, liver transplantation remains the cornerstone of long-term survival in HRS, and
continued advances in molecular research, biomarker discovery, and personalized medicine
promise to further enhance outcomes. A multidisciplinary approach integrating hepatology,
nephrology, and critical care is essential for optimizing care in this vulnerable population.
References
1. Albertoni, M., & Schrier, R. W. (2001). Hemodynamic and hormonal characteristics of
cirrhotic patients with functional renal failure. Kidney International, 59(4), 1658–1665.
https://doi.org/10.1046/j.1523-1755.2001.0590041658.x
2. Arroyo, V., Fernández, J., & Ginès, P. (2006). Pathogenesis and treatment of hepatorenal
syndrome. Seminars in Liver Disease, 26(4), 283–296. https://doi.org/10.1055/s-2006-948308
3. Ginès, P., Schrier, R. W. (2009). Renal failure in cirrhosis. New England Journal of
Medicine, 361(13), 1279–1290. https://doi.org/10.1056/NEJMra0809139
4. Nadim, M. K., Kellum, J. A., Davenport, A., Wong, F., Davis, C., & Pannu, N. (2016).
Hepatorenal syndrome: Update on diagnosis, pathophysiology, and treatment. American Journal
of Kidney Diseases, 67(4), 660–678. https://doi.org/10.1053/j.ajkd.2015.10.043
5. Salerno, F., Gerbes, A., Ginès, P., Wong, F., Arroyo, V. (2007). Diagnosis, prevention and
treatment of the hepatorenal syndrome in cirrhosis. Gut, 56(9), 1310–1318.
https://doi.org/10.1136/gut.2006.107789
6. Wong, F. (2015). Recent advances in our understanding of hepatorenal syndrome. Nature
Reviews Nephrology, 11, 265–276. https://doi.org/10.1038/nrneph.2015.34
7. Zaher, A., Al-Khafaji, A., & Kellum, J. A. (2020). Hepatorenal syndrome: The role of
inflammation.
Current
Opinion
in
Critical
Care,
26(6),
548–554.
